Insys Therapeutics has launched Subsys fentanyl sublingual spray to manage recurring cancer pain, according to Pharmaceutical Business Review.
The spray is available in 100mcg through 1600mcg doses and intended for cancer patients ages 18 years and older who are tolerant to opioid therapy for underlying persistent cancer pain.
Subsys is a sublingual spray formulation of fentanyl in a single unit-dose delivery device that disperses a fine mist over a broad area. In clinical trials, it reached the primary endpoint of summed pain intensity differences at 30 minutes post-treatment.
Tennessee Pain Bill Faces Opposition from Lawmakers, Physicians
Editorial: Kentucky Medical Association President Opposes Current Pain Clinic Legislation
The spray is available in 100mcg through 1600mcg doses and intended for cancer patients ages 18 years and older who are tolerant to opioid therapy for underlying persistent cancer pain.
Subsys is a sublingual spray formulation of fentanyl in a single unit-dose delivery device that disperses a fine mist over a broad area. In clinical trials, it reached the primary endpoint of summed pain intensity differences at 30 minutes post-treatment.
Related Articles on Pain Management:
Interventional Pain Management Physician Dr. John Hume Joins Houston's KSF Orthopaedic CenterTennessee Pain Bill Faces Opposition from Lawmakers, Physicians
Editorial: Kentucky Medical Association President Opposes Current Pain Clinic Legislation